May 7, 2021 —  RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced artificial intelligence (AI) and computer vision solutions, announced today a new prostate MRI-to-ultrasound registration tool. The tool’s fully automated, d

May 7, 2021 — RapidAI, a leader in advanced cerebrovascular imaging, announced the expansion of RapidAI Insights, a unique analytics solution that uses Rapid scan, treatment, and outcome data to enable hospitals and hospital systems to make more informed business decisions, reduce costs across s

May 6, 2021 — GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved

May 6, 2021 — Individuals living with severe Alzheimer's disease showed remarkable improvements in behavior and cognition within days of receiving an innovative new treatment that delivered low doses of radiation, a recent Baycrest-Sunnybrook pilot study found.

May 6, 2021 — Magnetic Resonance Imaging (MRI) images are usually meant to be static.

May 6, 2021 — Omega Medical Imaging, an innovator in AI image-guided interventional systems for hospitals and healthcare facilities around the worl

May 6, 2021 — Forbes recently announced that Nines, Inc. has been selected one of 50 most promising private AI companies in the US and Canada. The Forbes AI 50 highlights companies that are using artificial intelligence (AI) in meaningful ways and demonstrating business potential.

May 5, 2021 — Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer death, with about 80% of the total 154,000 deaths recorded each year caused by cigarette smoking. Black men are more likely to develop and die from lung cancer than persons of any other racial or ethnic group, pointing to severe racial disparities.

May 5, 2021 — For patients with brain metastases, amino acid positron emission tomography (PET) can provide valuable information about the effectiveness of state-of-the-art treatments. When treatment monitoring with contrast-enhanced magnetic resonance imaging (MRI) is unclear, adding 18F-FET PET can help to accurately diagnose recurring brain metastases and reliably assess patient response.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now